Industry & Policy News

[Kyverna Therapeutics] Kyverna Therapeutics and ElevateBio, LLC announced a partnership to advance process development and manufacturing to produce industry-leading Ingenui-T-derived chimeric antigen receptor (CAR) T-cell therapies.

[Indiana University] A breast cancer researcher at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center received a five-year, $2.2 million grant from the National Cancer Institute to examine how certain immune cells support metastatic breast cancer development—and how to stop it.

[The CHUM Foundation (Newswire.ca)] The CHUM Foundation is pleased to announce that the Montreal Cancer Institute is contributing $500,000 to the Guy Lafleur Fund for Cancer Research. This major contribution will help propel the ambitious and promising ideas of the teams at the CHUM Research Centre, aiming to achieve major breakthroughs in precision oncology and ultimately defeating the disease.

[Nature News] This year’s Nobel Prize in Physiology or Medicine has been awarded to biochemist Katalin Karikó and immunologist Drew Weissman for discoveries that enabled the development of mRNA vaccines against COVID-19.

[Science] In a development that has alarmed conservation biologists, the avian flu strain that has devastated birds and marine mammals on five continents has reached Ecuador’s Galápagos National Park, home to species that are found nowhere else.

[Science] Since early in the pandemic, researchers and physicians have known all too well that COVID-19 can affect various organs, such as the brain, lungs, heart, and kidneys. But how long does the damage linger, and what does it mean for a patient’s recovery? Imaging studies investigating long-term effects of COVID-19 have often focused on one organ at a time, limiting what scientists could learn about the disease’s internal impact.